1 / 5

Global Prevention and Treatment of Pediatric HIV-1 Infection

Global Prevention and Treatment of Pediatric HIV-1 Infection. Katherine Luzuriaga, M.D. Professor Pediatrics & Molecular Medicine UMMS. Pediatric HIV/AIDS: 2005. 2.5 million infants at risk for MTCT. 620,000 newly infected per year.

masato
Télécharger la présentation

Global Prevention and Treatment of Pediatric HIV-1 Infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Prevention and Treatment of Pediatric HIV-1 Infection Katherine Luzuriaga, M.D. Professor Pediatrics & Molecular Medicine UMMS

  2. Pediatric HIV/AIDS: 2005 • 2.5 million infants at risk for MTCT. • 620,000 newly infected per year. • Industrialized countries: ART have markedly decreased MTCT and pediatric HIV-related morbidity and mortality. • Resource limited settings: Simplified ART regimens can prevent MTCT but implementation has been difficult; half of HIV infected children die by their second birthday.

  3. International Clinical Trials Prevention of MTCT: PACTG: Phase I-III Nevirapine Trials South Africa: South African Intrapartum Nevirapine Trial IMPAACT: International Pediatric Adolescent and Adult AIDS Clinical Trials Group Pediatric Treatment: Cambodia: Modified DOT Trial in Children • Dr. Sam Sophan, National Pediatric Hospital, Phnom Penh IMPAACT

  4. Pediatric HIV-1 Vaccine: Rationale • ART efficacy will be limited by cost, logistical issues, and the emergence of resistance. • Neonatal immunization may not only protect against perinatal and breast milk HIV-1 transmission, but may also form the basis for lifetime immunity. • Neonatal immunizations utilize existing infrastructure for delivery of childhood vaccines.

  5. MVA/Fowlpox Vaccine Milestones

More Related